The Times Are Changin

llergan plc (NYSE:AGN) announced that it has received approval from the U.S. Food and Drug Administration or FDA to market JUVEDERM ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVEDERM ULTRA XC instantly adds fullness to the lips and is the only dermal filler that has proven results lasting up to one year for lip augmentation, the company said.

Allergan plc (NYSE:AGN)’s stock on 02 October traded at beginning with a price of $278.12 and when day-trade ended the stock finally moved up 2.00% to end at $288.00. Allergan plc (NYSE:AGN)’s showed weekly performance of 3.21%.

Apricus Biosciences, Inc. (NASDAQ:APRI) announced it has signed an exclusive distribution agreement with Ferring Pharmaceuticals to market Vitaros (alprostadil), its topical on-demand product for the treatment of erectile dysfunction, in Latin American countries. Apricus will receive $2.25 million from Ferring in an upfront payment. Apricus is also eligible to receive up to $16 million in regulatory and sales milestone payments, in addition to royalties based on Ferring’s net sales of the product in the territory.

Return on Investment for Apricus Biosciences, Inc. (NASDAQ:APRI) is -337.30% and on Friday its shares closed at $1.54. Apricus Biosciences, Inc. (NASDAQ:APRI) monthly performance stands at -8.88% while its year to date performance is 54.00%.

CryoLife Inc. (NYSE:CRY), announced that it participated in the upcoming Ladenburg Thalmann 2015 Healthcare Conference on Tuesday, September 29, 2015 at the Sofitel Hotel in New York.

CryoLife Inc. (NYSE:CRY) shares increased 1.52% on last trading day to close the day at $10.04. Company price to sale ratio is 1.98 and has 7.60% insider ownership. CryoLife Inc. (NYSE: